<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J. Infect. Dis</journal-id><journal-id journal-id-type="hwp">jinfdis</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-title-group><journal-title>The Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>The University of Chicago Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8985191</article-id><article-id pub-id-type="pmc">7109964</article-id><article-id pub-id-type="doi">10.1093/infdis/175.1.16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Articles</subject></subj-group></article-categories><title-group><article-title>A Genetically Inactivated Herpes Simplex Virus Type 2 (HSV-2) Vaccine Provides Effective Protection against Primary and Recurrent HSV-2 Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boursnell</surname><given-names>M. E. G.</given-names></name><xref ref-type="corresp" rid="cor1"/><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Entwisle</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Blakeley</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Duncan</surname><given-names>I. A.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Chisholm</surname><given-names>S. E.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>G. M.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Jennings</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>N&#x000ed; Challana&#x000ed;n</surname><given-names>D.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Sobek</surname><given-names>I.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>Inglis</surname><given-names>S. C.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib><contrib contrib-type="author"><name><surname>McLean</surname><given-names>C. S.</given-names></name><xref ref-type="aff" rid="d420432e162"/></contrib></contrib-group><aff id="d420432e162">
<institution>Cantab Pharmaceuticals Research Ltd., Cambridge, and Department of Experimental and Clinical Microbiology, Medical School, University of Sheffield</institution>, <addr-line>Sheffield, United Kingdom</addr-line></aff><author-notes><corresp id="cor1">Reprints or correspondence: Dr. M. E. G. Boursnell, Cantab Pharmaceuticals
Research Ltd., 184 Cambridge Science Park, Milton Rd., Cambridge CB4 4GN, United Kingdom.</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>1997</year></pub-date><pub-date pub-type="epub" iso-8601-date="1997-01-01"><month>1</month><year>1997</year></pub-date><pub-date pub-type="pmc-release"><month>1</month><year>1997</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>175</volume><issue>1</issue><fpage>16</fpage><lpage>25</lpage><history><date date-type="received"><day>28</day><month>11</month><year>1995</year></date><date date-type="rev-recd"><day>21</day><month>8</month><year>1996</year></date></history><permissions><copyright-statement>&#x000a9; 1997 by the University of Chicago</copyright-statement><copyright-year>1997</copyright-year><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri xlink:href="175-1-16.pdf"/><abstract><title>Abstract</title><p>A glycoprotein H (gH)-deleted herpes simplex virus type 2 (HSV-2) was evaluated as a vaccine for the prevention of HSV-induced disease. This virus, which we term a DISC (disabled infectious single cycle) virus, can only complete one replication cycle in normal cells and should thus be safe yet still able to stimulate broad humoral and cell-mediated antiviral immune responses. A gH-deleted HSV-2 virus that has been tested as a vaccine in the guinea pig model of recurrent HSV-2 infection was constructed. Animals vaccinated with DISC HSV-2 showed complete protection against primary HSV-2&#x02013;induced disease, even when challenged 6 months after vaccination. In addition, the animals were almost completely protected against recurrent disease. Even at low vaccination doses, there was a high degree of protection against primary disease. A reduction in recurrent disease symptoms was also observed following therapeutic vaccination of animals already infected with wild type HSV-2.</p></abstract></article-meta></front></article>